HIV/AIDS

Smart Home Healthcare Market by Technology, by Service, by Application, by Geography - Global Market Size, Share, Development, Growth and Demand Forecast, 2013-2023

Retrieved on: 
Wednesday, November 14, 2018
Health, Security engineering, Crime prevention, Medical terminology, Medicine, Prevention, Preventive healthcare, HIV/AIDS, Computer security, Nutrition

Of these, cellular network attained the largest revenue in the market, accounting for 64.2% share in 2017.

Key Points: 
  • Of these, cellular network attained the largest revenue in the market, accounting for 64.2% share in 2017.
  • This leading position of the category is attributed to its easy accessibility by consumers and ease of use.
  • Based on application, the smart home healthcare market is categorized into fall prevention and detection, safety and security monitoring, health status monitoring, nutrition/diet monitoring, memory aids, and others.
  • Among these, fall prevention and detection application accounted for the largest share, with 39.0% contribution in 2017 in the global market.

U.S. Intravenous Immunoglobulin (IVIG) Market Analysis & Outlook (2018-2025): Stringent Regulations Pertaining to Production & Approval is Hampering Growth

Retrieved on: 
Thursday, November 8, 2018
Medicine, Immunology, Clinical medicine, Immunodeficiency, Primary immunodeficiency, Immunoglobulin therapy, Gamma globulin, Hypogammaglobulinemia, HIV/AIDS, Selective immunoglobulin A deficiency

The U.S. intravenous immunoglobulin (IVIG) market size is expected to reach USD 5.04 billion by 2025.

Key Points: 
  • The U.S. intravenous immunoglobulin (IVIG) market size is expected to reach USD 5.04 billion by 2025.
  • The market is estimated to witness a noteworthy CAGR of 6.1% over the forecast period.
  • Rising prevalence of primary and acquired immunodeficiency diseases such as congenital AIDS and hypogammaglobulinemia is a major growth driver of this market.
  • Rising cases of primary immune deficiency diseases are expected to drive the demand for fast, accurate, and safe treatment options, thereby boosting the market growth.

20th Anniversary of National Aboriginal AIDS Awareness Week

Retrieved on: 
Tuesday, November 6, 2018
HIV/AIDS, Health, Ribbon symbolism, Medicine, AIDS Awareness Week, World AIDS Day, Canadian AIDS Society, J. Kevin Barlow

OTTAWA, Nov. 6, 2018 /CNW/ -The Canadian Aboriginal AIDS Network (CAAN) announces Indigenous leadership and their supporters will celebrate its 20th Anniversary of Aboriginal AIDS Awareness Week on November 29, 2018 in Ottawa, ON with a Parliamentary Breakfast followed by December 1 6, 2018 events across the country (Vancouver, Edmonton, Peace River, Grande Prairie, Saskatoon, Winnipeg and more) to unite an Indigenous response to HIV and AIDS in a similar theme to World AIDS Day: Health For All Know Your Status.

Key Points: 
  • OTTAWA, Nov. 6, 2018 /CNW/ -The Canadian Aboriginal AIDS Network (CAAN) announces Indigenous leadership and their supporters will celebrate its 20th Anniversary of Aboriginal AIDS Awareness Week on November 29, 2018 in Ottawa, ON with a Parliamentary Breakfast followed by December 1 6, 2018 events across the country (Vancouver, Edmonton, Peace River, Grande Prairie, Saskatoon, Winnipeg and more) to unite an Indigenous response to HIV and AIDS in a similar theme to World AIDS Day: Health For All Know Your Status.
  • For over 20 years Aboriginal AIDS Awareness Week has provided HIV prevention, treatment and support resources and worked with Indigenous communities to empower them to address infectious diseases.
  • Aboriginal AIDS Awareness Week 2018 will also act as a platform for CAAN to continue to lobby for an urgent review of the HIV and Hepatitis C Community Action Fund, which has left so many long-standing organizations crippled by reduced funding or no funding.
  • "CAAN's severely reduced funding decimates the leading voice of First Nations, Inuit, and Mtis peoples living with HIV or AIDS and will have severe consequences on both Indigenous health and reconciliation," states Ken Clement, CEO of Canadian Aboriginal AIDS Network.

Global Kaposi's Sarcoma Market and Competitive Landscape 2014-2023 - Develop Forecast Models, Healthcare Frameworks & Economic Models

Retrieved on: 
Monday, October 29, 2018
Cancer, HIV/AIDS, Sarcoma, Kaposi's sarcoma, RTT, Kaposi

The "Global Kaposi's Sarcoma Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Kaposi's Sarcoma Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Kaposi's Sarcoma Market and Competitive Landscape - 2018, provides comprehensive insights into Kaposi's Sarcoma pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • This study accurately estimates and forecast Kaposi's Sarcoma market size and drug sales.
  • The research is classified into following sections - Kaposi's Sarcoma overview with definitions, symptoms, etiology, diagnosis, treatment options; Kaposi's Sarcoma pipeline insights covering late stage clinical trials pipeline; Kaposi's Sarcoma prevalence trends by countries; Kaposi's Sarcoma market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.

Continued declines in HIV research funding put global prevention targets at great risk

Retrieved on: 
Thursday, October 25, 2018
Pandemics, HIV/AIDS, Health, HIV, Lentiviruses, Epidemiology of HIV/AIDS, Epidemiology, Medicine, Health in Uganda, HIV/AIDS in China, HIV/AIDS in Rwanda

Sustained funding is critical to keep the full gamut of HIV prevention research moving forward in a timely manner.

Key Points: 
  • Sustained funding is critical to keep the full gamut of HIV prevention research moving forward in a timely manner.
  • Even small declines in funding can delay or sideline promising, new HIV prevention options that are needed to end the HIV epidemic.
  • "It is unacceptable that donor funding for HIV prevention research continues to fall year after year even as research is moving new options closer to reality.
  • The US government continued to be the major funder of HIV prevention research, contributing almost three-fourths of overall funding.

IAVI and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products for HIV

Retrieved on: 
Monday, October 22, 2018
Medicine, Health, Immunology, Immune system, HIV/AIDS, Antibodies, HIV vaccine, International AIDS Vaccine Initiative, Serum Institute of India, Vaccine, Monoclonal antibody, Neutralizing antibody

NEW YORK, Oct. 22, 2018 /PRNewswire/ -- The International AIDS Vaccine Initiative (IAVI) and Serum Institute of India, the world's largest vaccine manufacturer, today announced a strategic partnership to develop and manufacture affordable and accessible monoclonal antibody products for HIV and other global health challenges.

Key Points: 
  • NEW YORK, Oct. 22, 2018 /PRNewswire/ -- The International AIDS Vaccine Initiative (IAVI) and Serum Institute of India, the world's largest vaccine manufacturer, today announced a strategic partnership to develop and manufacture affordable and accessible monoclonal antibody products for HIV and other global health challenges.
  • Serum Institute is committed to developing high quality, affordable, monoclonal antibodies with the potential to treat and prevent HIV and other diseases in India and across the globe."
  • Some of these bNAbs are now being explored for their potential ability to prevent, treat, and cure HIV infection.
  • Serum Institute is developing biosimilars of existing antibody immunotherapies for a range of diseases, and in 2017 launched a novel monoclonal antibody against rabies.

Government of Canada takes steps to address high rates of HIV and hepatitis C among people who share drug-use equipment

Retrieved on: 
Thursday, October 11, 2018
Medicine, Health, Healthcare-associated infections, Immunology, Prevention of HIV/AIDS, HIV/AIDS, Pandemics, Women's health, Hepatitis, HIV/AIDS in Australia, HIV/AIDS in China

The projects to be funded will be based in communities that have high rates of hepatitis C and HIV.

Key Points: 
  • The projects to be funded will be based in communities that have high rates of hepatitis C and HIV.
  • "Community organizations do important work to reduce hepatitis C and HIV infections among people who share drug-use equipment.
  • This funding will support community initiatives to address the risk of HIV and hepatitis C infection among people who share drug-use equipment.
  • People who share drug-use equipment continue to be disproportionately represented among those acquiring new hepatitis C and HIV infections in Canada.

ONE® launches new myONE® condoms with 3 major improvements: 60 condoms sizes, now with an even more perfect feel

Retrieved on: 
Wednesday, October 10, 2018
Medicine, Health, Immunology, HIV/AIDS, Condom, Penis, RTT, Sexual health, Female condom, FITkit

After hearing customer feedback and using their exclusive condom manufacturing technology, ONE Condoms launches an even better feeling myONE condom with three major improvements.

Key Points: 
  • After hearing customer feedback and using their exclusive condom manufacturing technology, ONE Condoms launches an even better feeling myONE condom with three major improvements.
  • The original myONE launched in fall 2017 with rave reviews from people across the country, praising the difference proper condom fit makes in their sex lives.
  • Unlike regular condom manufacturing, myONE condoms are fully lubricated prior to being rolled and wrapped.
  • In order to buy myONE condoms, customers use a FitKit or a measuring tape to measure their length and circumference, and receive a unique myONE size code.

IAVI Announces Clinical Trial of Next-Generation HIV Vaccine Candidate Designed to Induce Antibodies to Block HIV Infection

Retrieved on: 
Tuesday, October 9, 2018
HIV/AIDS, Medicine, Vaccines, Health, International AIDS Vaccine Initiative, HIV vaccine, SAV001, H5N1 clinical trials

The trial will evaluate the safety of the candidate and the immune responses it is able to induce.

Key Points: 
  • The trial will evaluate the safety of the candidate and the immune responses it is able to induce.
  • The candidate, known as eOD-GT8 60mer, represents an important step forward in the quest to develop an HIV vaccine.
  • "The world urgently needs new ways to prevent HIV infection, and chief among these is a vaccine," said Mark Feinberg, M.D., Ph.D., president and CEO of IAVI.
  • These sites of vulnerability on the virus were then used to design vaccine immunogens, using what is referred to as a structure-based vaccine design approach.

Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027

Retrieved on: 
Thursday, September 20, 2018
Virology, Betaherpesvirinae, Viral diseases, Microbiology, Cytomegalovirus, CMV, HIV/AIDS, Medicine, Ethers, Purines, Cytomegalovirus colitis, Congenital cytomegalovirus infection

The Cytomegalovirus (CMV) market is expected to experience moderate growth over the forecast period (2017-2027).The market features several antivirals that are used for both treatment of clinically significant Cytomegalovirus (CMV) infections and prophylaxis in patients considered at high risk for Cytomegalovirus (CMV) infection.

Key Points: 
  • The Cytomegalovirus (CMV) market is expected to experience moderate growth over the forecast period (2017-2027).The market features several antivirals that are used for both treatment of clinically significant Cytomegalovirus (CMV) infections and prophylaxis in patients considered at high risk for Cytomegalovirus (CMV) infection.
  • The global Cytomegalovirus (CMV) market across the 7MM (US, France, Germany, Italy, Spain, the UK and Japan) was valued over $240M in 2017.
  • Over the 10-year forecast period, the Cytomegalovirus (CMV) market is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.5%.
  • The report "Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027", helps in analyzing the cytomegalovirus (CMV) market and treatment landscape, providing an overview and forecast of the market dynamics from 2017 to 2027.